{ }
001122334455554433221100
001122334455554433221100

Deutsche Bank downgrades Altria citing valuation and regulatory challenges

Deutsche Bank has downgraded Altria Group to "Hold" from "Buy," citing limited upside after a strong rally and ongoing regulatory challenges affecting its NJOY e-vapor business. Despite a 15% gain this year and attractive cash flow and dividend yield, the firm believes the stock is fairly valued at current levels, maintaining a $60 price target with only 2% upside potential. Altria faces regulatory hurdles following a ruling that its NJOY products infringe on Juul Labs' patents, impacting future prospects.

Altria faces downgrade from Deutsche Bank amid near-term challenges

Access to the page has been denied. Altria has been downgraded by Deutsche Bank due to facing near-term headwinds. This decision reflects concerns about the company's current challenges in the market.

deutsche bank downgrades altria group to hold with sixty dollar target

Deutsche Bank has downgraded Altria Group, Inc. from Buy to Hold, setting a price target of $60. The company operates primarily in tobacco manufacturing, with 88.3% of net sales from cigarettes, including brands like Marlboro and L&M, and 11.5% from smokeless tobacco products such as Copenhagen and Skoal.

Deutsche Bank lowers Altria Group rating to hold after significant rally

Deutsche Bank has downgraded Altria Group to a Hold rating following a significant 15% rally in the company's stock year-to-date. This decision reflects a cautious outlook after the recent gains in Altria's market performance.

ubs raises altria group price target to 46 maintains sell rating

UBS has raised its price target on Altria Group, Inc. to $46 from $42 while maintaining a sell rating. The company operates primarily in tobacco manufacturing, with 88.3% of net sales from cigarettes, 11.5% from smokeless tobacco products, and 0.2% from other activities.

Altria price target increased to 46 by UBS analyst

UBS analyst Faham Baig has raised the price target for Altria (NYSE: MO) to $46. This adjustment reflects the firm's updated outlook on the stock as of April 1, 2025.

analysts upgrade british american tobacco while top stocks remain unlisted

British American Tobacco (NYSE:BTI) has received a "buy" rating from UBS Group, upgraded from "neutral," while Barclays has given it a "strong-buy" rating. However, analysts from StockNews.com and Morgan Stanley have downgraded the stock, reflecting mixed sentiments in the market. Currently, BTI shares are trading at $37.93, with a 12-month range of $28.25 to $39.54, and institutional investors hold 16.16% of the company's stock.

solana's resurgence and potential in the evolving cryptocurrency landscape

Solana, a cryptocurrency launched in 2020, has experienced significant price volatility, peaking at $259 in 2021 before dropping below $10 in late 2022. Despite its rocky history, including a connection to the FTX collapse, Solana has regained investor trust, showcasing robust developer interest and increasing transaction volumes, positioning itself as a key player in the Web3 ecosystem. With a market cap of $99 billion, it ranks as the sixth most valuable cryptocurrency, indicating strong potential for future growth amid evolving market conditions.

altria group reports strong earnings and revenue growth in latest quarter

Altria Group (NYSE: MO) reported Q3 earnings of $1.38 EPS, exceeding estimates of $1.35, with revenues of $6.26 billion, surpassing expectations of $5.33 billion. The company has a net margin of 42.82% and a negative return on equity of 233.80%. Analysts predict an EPS of 5.11 for the current fiscal year, while the stock has a consensus "Hold" rating and an average target price of $51.33.
12:00 29.11.2024

Cramer expresses caution on various stocks including Altria and Boeing

Cramer's Lighting Round highlighted concerns over several stocks. Altria is deemed undervalued but not recommended due to health implications. Boeing is avoided for potential long-term losses, while Becton Dickinson faces challenges linked to vaccine business risks. IDEAYA Biosciences is considered too early-stage for investment, and AstraZeneca's uncertain trajectory raises alarms about further declines.
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.